Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Cipla has announced that the United States Food and Drug Administration (USFDA) has classified its recent inspection of the company's manufacturing facility in Bommasandra, Bengaluru as Voluntary ...

Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the current Good ...

Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates ...

Cipla reports a 10% YoY rise in Q1FY26 net profit, driven by strong performance in consumer healthcare and generics. The ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla reported a 10% increase in consolidated profit after tax, reaching ₹1,298 crore for Q1 FY26, driven by strong sales in ...

Cipla is looking at the whole GLP-1 category and not just Semaglutide alone, says Cipla CEO Umang Vohra in a post-results ...

Ciplas Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 1,778 crore, reflecting a 4% YoY ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Mumbai-based pharmaceutical major Cipla has reported its financial results for the April-June period, with a ...